Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone de...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Ray89c Jan. 14 at 1:54 PM

KULR told you guys . Hold $KULR $ALUR $TNYA and print money.

1 · Reply

Rolfthewild Jan. 14 at 11:47 AM

$TNYA hello what do we have here?

1 · Reply

blocktrade Jan. 14 at 9:59 AM

$TNYA MS cut their pt in Turdnaya last week from 5 to 2 💩

1 · Reply

grw1974 Jan. 14 at 1:03 AM

$VKTX $TNYA $ARWR an overview from Switzerland. Our most renowned Newspaper NZZ published the following list showing the money that BP has available based on net debt max 3x EBITDA - in billions. So there should be some deals in the pipeline. Published last Saturday before the conference.

0 · Reply

Matthew2002 Jan. 13 at 7:54 PM

$TNYA just fyi this is a 2-5 year play this is not gonna get you rich quick, just accumulate shares and forget it, it will pay off GLL

1 · Reply

HMoody69 Jan. 13 at 4:22 PM

$TNYA

0 · Reply

Quantumup Jan. 13 at 12:20 PM

Oppenheimer reiterated $LXEO Outperform-$20 $RCKT $TNYA $LRMR $BIIB VYGR DSGN PTCT Oppenheimer said in its note: We believe yesterday's interim look from LX2020's Phase 1/2 HEROIC study in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) yielded clear efficacy signals across the high-dose cohorts accompanied by unconcerning safety observations. With shares having closed down 23% vs. a flat XBI, the market may have been looking for a more consistent relationship between PKP2 increase and arrhythmia improvement-but we emphasize that the data remain immature, and look forward to 12-month follow-up results from all high-dose participants in 4Q26. We regard the selloff as having made the shares more attractive in view of LX2006's opportunity in Friedreich's ataxia ($1B+ US peak sales opportunity), which remains the key LXEO investor focus in our view and for which Phase 2 remains on track to begin in 1H.

1 · Reply

Cel55 Jan. 13 at 9:21 AM

$TNYA I wish everyone a blessed day. I hope the clinical data will be positive, and I believe that the sideways movement observed until the announcement of the clinical results is temporary and that the price may rise above 1 dollar over time. Options expire on January 16, and since the maximum loss level for these options is around USD 0.50, the strongest downward technical pressure on the price may occur on that day; however, the main decisive move is expected to emerge after January 16, once this pressure is lifted.

0 · Reply

Ommo Jan. 12 at 8:19 PM

$TNYA "Guys, we know everyone’s spirits might be a bit low since Tenaya’s been stuck around that 78 to 80 cent range for the past 10-15 days and hasn’t really broken out. But we just want to lift everyone’s mood a bit and let you know that positive news is on the way. Between February and March, we’re expecting to see the stock climb above $1.25 or $1.50, and it could even reach $2.X before any reverse split happens. So things are looking up, and the coming days should be better!"

2 · Reply

DrGonzo69 Jan. 12 at 6:31 PM

$TNYA it's only been 19 closing days below $1. I think we are well positioned for +$1 soon.

2 · Reply

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Dec 12, 2025, 1:56 PM EST - 4 weeks ago

Tenaya Stock Plunges After $60 Million Equity Offering

Dec 12, 2025, 12:16 AM EST - 4 weeks ago

Tenaya Therapeutics Announces Pricing of Public Offering

Dec 11, 2025, 10:42 PM EST - 4 weeks ago

Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript

Dec 11, 2025, 4:02 PM EST - 4 weeks ago

Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:01 PM EST - 4 weeks ago

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Dec 11, 2025, 4:01 PM EST - 4 weeks ago

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Nov 10, 2025, 3:11 PM EST - 2 months ago

Tenaya Therapeutics, Inc. (TNYA) Shareholder/Analyst Call Transcript

Nov 8, 2025, 11:25 AM EST - 2 months ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Nov 4, 2025, 5:30 PM EST - 2 months ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 4:05 PM EDT - 3 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 2, 2025, 4:05 PM EDT - 3 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Sep 18, 2025, 4:05 PM EDT - 4 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2025, 11:07 PM EDT - 4 months ago

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 31, 2025, 10:15 AM EDT - 4 months ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 8, 2025, 8:00 AM EDT - 5 months ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 5 months ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:30 AM EDT - 6 months ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 13, 2025, 8:30 AM EDT - 8 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 9 months ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 10 months ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 10 months ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 10 months ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 10, 2025, 4:05 PM EDT - 11 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:00 AM EST - 11 months ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 1 year ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 16, 2024, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Feb 26, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 2 years ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 3, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 2 years ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:19 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Ray89c Jan. 14 at 1:54 PM

KULR told you guys . Hold $KULR $ALUR $TNYA and print money.

1 · Reply

Rolfthewild Jan. 14 at 11:47 AM

$TNYA hello what do we have here?

1 · Reply

blocktrade Jan. 14 at 9:59 AM

$TNYA MS cut their pt in Turdnaya last week from 5 to 2 💩

1 · Reply

grw1974 Jan. 14 at 1:03 AM

0 · Reply

Matthew2002 Jan. 13 at 7:54 PM

$TNYA just fyi this is a 2-5 year play this is not gonna get you rich quick, just accumulate shares and forget it, it will pay off GLL

1 · Reply

HMoody69 Jan. 13 at 4:22 PM

$TNYA

0 · Reply

Quantumup Jan. 13 at 12:20 PM

1 · Reply

Cel55 Jan. 13 at 9:21 AM

0 · Reply

Ommo Jan. 12 at 8:19 PM

2 · Reply

DrGonzo69 Jan. 12 at 6:31 PM

$TNYA it's only been 19 closing days below $1. I think we are well positioned for +$1 soon.

2 · Reply

wins2love Jan. 12 at 5:45 PM

$TNYA Penny stocks and used car lots have a lot in common. Most people buying/selling don’t really understand the value of the asset. Even with online sites that help people see the value of a car, car dealers buy them below market and sell them above market all day long. The same thing happens with stocks, especially micro caps. No matter how many buy and/or hold ratings a stocks has, there will ALWAYS be people selling it below market. Then when the stock starts moving toward the forecasted targets, the same people will pay more than they sold their previous shares for. That’s human nature! The good thing is people rebalancing portfolios to start the year get to stock up at very reasonable prices and hopefully spend a lot of 2026 in the black. Happy Hunting Longs! ❤️🙏🏽

0 · Reply

Ray89c Jan. 12 at 3:52 PM

$TNYA buy now. Lower orders filled. Hold and be patient.

1 · Reply

blocktrade Jan. 12 at 3:38 PM

$TNYA they released all that nonsense on Friday and it did absolutely nothing. 💩

0 · Reply

Chapter7 Jan. 12 at 2:41 PM

$TNYA never fails to let me down. Should’ve figured, we were up 5% overnight after all

2 · Reply

Mtstone8 Jan. 10 at 6:42 PM

$TNYA

0 · Reply

Ommo Jan. 9 at 5:52 PM

$TNYA "Good evening, everyone! We just wanted to let you know that Tenaya has announced they'll be presenting updates on TN-201 and TN-401 in the first half of 2026—basically from the start of '26 up to mid-year. The news looks quite positive and encouraging, and that should definitely give our smaller investors a nice morale boost.

0 · Reply

Crazyrussiankid Jan. 9 at 4:10 PM

$TNYA something’s gotta give…. Ship shall not sink… not yet. I believe we will make it to the promise land soon $4+

0 · Reply

Psypsyd Jan. 9 at 3:57 PM

$TNYA News = further down. Every time

0 · Reply

Mbuck17 Jan. 9 at 3:13 PM

$TNYA This was a very positive sign from the Yahoo Finance article. I was under the impression they would need another cash raise in late 2026. Not the case. "Tenaya ended the third quarter of 2025 with $56.3 million in cash, cash equivalents and investments in marketable securities. With the additional proceeds of $60 million from the December 2025 public offering (prior to deducting underwriting discounts and commissions and offering expenses), the company expects that such resources will be sufficient to fund planned operations through mid-2027."

2 · Reply

JohnTrack Jan. 9 at 3:10 PM

$TNYA 2026 Strategic Priorities and Anticipated Milestones https://www.rapidticker.com/news/tnya-tenaya-therapeutics-announces-2026-strategic-218512

0 · Reply

Ray89c Jan. 9 at 3:00 PM

$TNYA hmm orders are stacking down instead up. .69 shows green box of orders. All the best

1 · Reply

BadyBady Jan. 9 at 2:56 PM

$TNYA "The most important aspect of this sector, referring to TNYA, is the availability of liquidity and the achievement of milestones. Liquidity has been sufficiently secured until mid-2027, and I believe milestones will be achieved well and progressively until mid-2027, and I expect we will see remarkable or even extraordinary achievements and news in the first quarter of 2026."

0 · Reply

Market Cap	122.75M
Revenue (ttm)	0.00
Net Income (ttm)	-111.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,722,400
Avg Vol	4,848,256
Day's Range	N/A - N/A
Shares Out	166.51M
Stochastic %K	57%
Beta	3.18
Analysts	Strong Sell
Price Target	$9.00